Objective: Assess whether CD70+ B cells contribute to EAE. Materials and methods: MOG-specific TCR transgenic mice (2D2) were crossed with mice with constitutive CD70 expression on B cells. The development of EAE and the phenotype of B-T lymphocytes were studied in 2D2xCD70 animals. Results: Spontaneous EAE developed in 20% of 2D2xCD70 and 3% of 2D2 mice. EAE was also more severe in 2D2xCD70 versus 2D2 animals upon MOG immunization. The susceptibility of 2D2xCD70 to EAE was associated with fewer FoxP3+ T cells. Conclusions: Expression of CD70 by B cells aggravates EAE possibly by reducing the number of regulatory T cells.
Introduction
B lymphocytes play important pathogenic roles in a wide variety of autoimmune diseases, as demonstrated by the association of autoimmune diseases with single nucleotide polymorphisms (SNPs) in molecules related to BCR signaling (Harley et al., 2008; Kozyrev et al., 2008; Arechiga et al., 2009; Habib et al., 2012) , defects in B cell central tolerance check points (Yurasov et al., 2005; Menard et al., 2011) , the presence of disease-specific autoantibodies (LaGasse et al., 2002; Arbuckle et al., 2003; Nielen et al., 2004) , and the clinical efficacy of B cell directed therapies in diseases such as rheumatoid arthritis (Edwards et al., 2004; Dorner et al., 2010) , type 1 diabetes (Pescovitz et al., 2009 ) and systemic lupus erythematosus (Looney et al., 2004; van Vollenhoven et al., 2004; Gunnarsson et al., 2007; Camous et al., 2008) . B cells also play a pivotal role in autoimmune diseases that are considered driven by pathogenic T cells, with as prototypical example multiple sclerosis (MS). MS does not display the genetic risk factors for B cell autoimmunity such as PTPN22 SNPs and myelin-directed autoantibodies are not thought to be fully pathogenic (Schluesener et al., 1987; Linington et al., 1988; Genain et al., 1995) . However, B cell depletion does have a beneficial effect in this T cell mediated disorder (Hauser et al., 2008) . These findings in patients are paralleled by studies in myelin oligodendrocytic glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) . This experimental MS model is heavily dependent on B cells (Gausas et al., 1982; Lyons et al., 1999) , even though knock-in of an MOG-reactive IgH gene does not result in pathology despite increased autoantibody titers (Litzenburger et al., 1998) . Using MOG-specific TCR transgenic animals (Bettelli et al., 2003) , we demonstrated that MOG-specific B cells contribute to pathology by capturing, processing and presenting autoantigen to autoreactive T cells, hence triggering pathogenic T cell autoimmunity rather than by increasing autoantibody titers (Bettelli et al., 2006; Krishnamoorthy et al., 2006) .
Besides TCR triggering by the MHC-antigen complex, T cell activation requires adequate costimulation by antigen presenting cells (APC) through molecular complexes such as CD40-CD40L (Grewal and Flavell, 1996; Elgueta et al., 2009 ), CD80/86-CD28 (Slavik et al., 1999; Carreno and Collins, 2002) , ICOS-ICOSL (Shilling et al., 2006; Simpson et al., 2010) , and CD70-CD27 Denoeud and Moser, 2011) . Most costimulatory molecules are not constitutively expressed on APCs but upregulated upon activation. Upregulation of costimulatory molecules is not only required for appropriate protective immune responses but also plays an important role in autoimmune disease, as they may contribute to the break tolerance. The role of the CD28-B7.1/B7.2 costimulation pathway in driving autoimmunity has been extensively studied (Harlan et al., 1994; Salomon et al., 2001) . Interference with these signals leads to significant protection in many experimental autoimmune models (Nurieva et al., 2009) , and abrogation of B7.1/B7.2 costimulation by CTLA4-Ig treatment is a highly effective treatment for human RA (Kremer et al., 2003) .
The CD27-CD70 pathway is also very important in costimulation of T cells (Watts, 2005) . A few studies report that its blockade is beneficial in EAE and colitis (Nakajima et al., 2000; Manocha et al., 2009 ). Nonetheless, its contribution to autoimmunity is less well understood and no therapeutic exploitation of these molecules in human autoimmune disorders has been reported yet. The role of B cells as APCs in T cell-mediated autoimmune diseases and the fact that costimulation can lower the activation threshold of T lymphocytes (van Gisbergen et al., 2011) , raise the question whether altered expression of costimulatory molecules on B cells would promote the activation of self-reactive T cells, triggering the progression from autoimmunity to overt autoimmune disease. To address this question, we crossed MOG-specific TCR transgenic mouse (2D2 mice) in which 5% of the animals develop spontaneous EAE (Bettelli et al., 2003) , with mice constitutively expressing CD70 on B lymphocytes (Arens et al., 2001) . We previously reported that B cell specific CD70 overexpression on a wild type TCR background induces strong activation and IFNγ production by effector T cells, (Arens et al., 2001) . In this study, we hypothesized that CD70 overexpression on B cells would have a similar effect on the MOG-specific autoreactive T cells, which in this model can be tracked as they express the TCR β-chain family β11 (vβ11) (Bettelli et al., 2003) , thus leading to a higher incidence and/or severity of EAE. If strong costimulation could cause overt autoimmune disease by modulating either the amplitude or the quality of the pathogenic and/or regulatory T cell response, the CD27-CD70 pathway could become a good therapeutic target in MS. Our results supported our hypothesis and showed that CD70 costimulation indeed triggered overt EAE, nevertheless, no changes were observed in the T cell effector compartment but rather in the regulatory T cell subset.
Materials and methods

Ethics statement
All animal experiments were performed according to The Netherlands local regulations and approved by the Animal Ethics Committee of the Academic Medical Center/University of Amsterdam.
Animals
2D2 transgenic C57BL/6J mice were provided by Dr. V. Kuchroo (Harvard Medical School, Boston, MA) (Bettelli et al., 2003) . CD70 F12 transgenic animals (Arens et al., 2001) were housed under SPF conditions in the animal facility of the Academic Medical Center/ University of Amsterdam (Amsterdam, The Netherlands). 2D2 mice were crossed with CD70 mice and the F1 generation of 2D2 and 2D2xCD70 littermates was used for EAE experiments.
Experimental autoimmune encephalomyelitis
Non-immunized mice (32 control 2D2 mice and 44 2D2xCD70 littermates) were observed for 20 weeks for the development of spontaneous EAE. In a second set of experiments, EAE was induced by subcutaneous immunization of 7-8 week old mice (16 control 2D2 animals and 18 2D2xCD70 littermates) with 13 μg of recombinant rat myelinoligodendrocyte glycoprotein (MOG) (amino acid residues 1-125) (AnaSpec, Freemont CA) emulsified in complete Freund's adjuvant (CFA) (Chondrex, Bellevue WA) and supplemented with 400 μg/ml of M. tuberculosis (Difco Laboratories, Sparks MD). Additionally, mice were injected intravenously on days 0 and 2 with 200 ng of pertussis toxin (Sigma-Aldrich, St. Louis MI). The animals were scored daily for clinical signs of EAE on a 5-point scale: 0 = no disease; 1 = decreased tail tone; 2 = hind-limb weakness or partial paralysis; 3 = complete hind-limb paralysis; 4 = front and hind limb paralysis.
Serology
For the analysis of MOG-specific autoantibodies, we collected plasma from mice in homeostatic conditions or after immunization with MOG protein. IgG antibodies specific for MOG were determined using the Anti-MOG (1-125aa) IgG ELISA Kit (AnaSpec) following the manufacturer's recommendations.
Flow cytometric detection of surface proteins
Spleens were collected from non-immunized mice and from animals immunized with MOG. Single-cell suspensions were obtained, erythrocytes removed, and cells were stained at 4°C with the indicated fluorochrome-conjugated anti-mouse monoclonal antibodies for surface markers or with isotype-and concentration-matched control antibodies. Antibodies used in this study included Alexa700-conjugated anti-CD3, Alexa700-conjugated anti-CD4, phycoerythrin (PE)-Cy7-conjugated anti-CD4, Alexa 780-conjugated anti-CD8, PE-conjugated antivβ11, FITC-conjugated anti-CD44 and APC-conjugated anti-CD62L (all eBioscience, San Diego, CA). Flow cytometric analysis was performed and analyzed using a 7-color FACS Canto (BD Biosciences, San Jose CA) and FlowJo software (Tree Star Inc., Ashland OR). The results are expressed as percentage of positive cells.
Analysis of T cell survival
To assess apoptosis and survival capacity, splenic T cells were recovered and stimulated for 72 h in vitro with MOG protein or anti-CD3/CD28 antibodies. Staining with 7-aminoactiomycin D (BD Biosciences) and APC-conjugated Annexin-V were used to quantify apoptotic and necrotic cells. The results are expressed as percentage of positive cells.
Analysis of T cell cytokine production
Splenic T cells were cultured in RPMI supplemented with 10% FCS, β-mercaptoethanol, L-glutamine, gentamicin sulfate and penicillin/ streptomycin, and stimulated in 96-well plates for 6 h with phorbol myristate acetate (PMA, 10 ng/ml; Sigma-Aldrich) and ionomycin (1 μM; Sigma-Aldrich). Alternatively, cells were stimulated with MOG protein (0.6, 1.6, 3 or 15 μg/ml; AnaSpec, Freemont, USA) or anti-CD3 (1 μg/ml) and anti-CD28 antibodies (1 μg/ml) (both kindly provided by Dr. L. Boon, Bioceros BV, Utrecht, NL) for 48 h. For the detection of intracellular cytokines, Brefeldin A (5 μg/ml; SigmaAldrich) was added for the last 4 h of culture, and cells were fixed and permeabilized using an intracellular staining kit (BD BioSciences). Cells were stained with Alexa 488-conjugated anti-IL-17, PerCP-Cy5.5-conjugated anti-IFNγ, PE-Cy7-conjugated anti-IL-2, and APC-conjugated anti-TNFα (eBiosciences).
Flow cytometric detection of FoxP3+ T cells
To quantify the percentage of FoxP3+ cells, splenic lymphocytes were recovered, fixed and permeabilized with the FoxP3 + Transcription Factor Staining Buffer Set (eBiosciences), and stained at 4°C with the indicated fluorochrome-conjugated anti-mouse monoclonal antibodies or with isotype-and concentration-matched control antibodies: Alexa700-conjugated anti-CD3, phycoerythrin (PE)-Cy7-conjugated anti-CD4, Alexa 780-conjugated anti-CD8, PEconjugated anti-vβ11 and APC-conjugated anti-FoxP3 (eBioscience). To assess the effect of CD70 overexpression on FoxP3 positive T cells in vitro, CD4+ and B220+ cells were purified from splenic single-cell suspensions using anti-CD4 and anti-CD19 antibodies conjugated to magnetic beads and MS columns (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). Cocultures of 5 × 10 6 T and 5×10 6 B cells/ml were set up in RPMI supplemented with 10% FCS, β-mercaptoethanol, L-glutamine, gentamicin sulfate and penicillin/streptomycin. Cells were cultured in 96-well plates with medium alone or medium supplemented with MOG peptide (1, 3 or 10 μg/ml; GenScript, Piscataway, NJ) or anti-CD3 (1 μg/ml) and anti-CD28 antibodies (1 μg/ml) (both provided by Dr. L. Boon, Bioceros BV, Utrecht, NL). Cells were recovered after 72 h and stained as indicated previously.
Statistics
Gehan-Breslow-Wilcoxon test was used to compare the incidence of EAE between groups of mice. Flow cytometric data were compared using Mann-Whitney non-parametrical t-test. P-values ≤0.05 were considered statistically significant.
Results
B cell-specific CD70 overexpression increased the susceptibility to EAE
Non-immunized 2D2 single transgenic mice and 2D2xCD70 mice were monitored daily for the development of spontaneous EAE up to 20 weeks of age. In line with published data (Bettelli et al., 2003) , only 1/32 (3%) 2D2 mice developed signs of neurological disease, starting at week 10 and reaching a maximal EAE score of 2. In contrast, 20% of the 2D2xCD70 mice (9/44, p = 0.03) developed spontaneous EAE (Fig. 1A) . The median disease onset was 12 weeks (range: 5-17), the median maximum score was 3 (range: 1-4), and the signs of disease followed the classical pattern of progressive paralysis from tail to hind limbs to front limbs. The severity of EAE, estimated by comparing the area under the curve of clinical scores in time per group, was also significantly higher in the 2D2xCD70 mice than in the 2D2 mice (p = 0.03, Fig. 1B) .
To study whether the constitutive expression of CD70 on B cells also enhanced the development of autoimmune disease after MOG immunization, 2D2 and 2D2xCD70 animals were injected with a low dose of recombinant MOG protein in CFA. As CD70 transgenic mice are characterized by a profound B cell depletion, we immunized the mice between week 7 and 8 of age because the number of B cells was still comparable between 2D2 and 2D2xCD70 mice at that age (data not shown). Clinical monitoring during 10 days indicated that upon immunization, EAE developed in 31% (5/16) of the single transgenic 2D2 mice versus 72% (13/18) of the 2D2xCD70 animals (p = 0.012) (Fig. 1C) . Signs of disease appeared in both groups around the same time (2D2: median day 9 (range: 6-9 days) versus 2D2xCD70: median day 8 (range: 8-9 days)). Nonetheless, the severity of EAE indicated by the area under the curve of the clinical scores of all animals per group, was significantly higher in the Fig. 1 . EAE development in 2D2xCD70 mice. 2D2xCD70 and 2D2 mice were observed from 6 to 20 weeks of age to record the development of spontaneous EAE. Neurological signs of disease were scored daily. At the end of the experiment, the incidence (A) and the severity (B) of spontaneous EAE were compared between groups. In a second experiment, 2D2xCD70 and 2D2 mice were immunized with a low dose of recombinant MOG protein. The development of EAE was monitored for 10 days and the neurological signs of disease were scored daily. The incidence (C) and the severity (D) of EAE were compared between groups. 2D2xCD70 animals (p = 0.02, Fig. 1D ). We were not able to observe disease over a longer time period as it is known that mice of the 2D2 background develop EAE of great severity upon immunization (Bettelli et al., 2003) . However, the data of these two experiments demonstrated that CD70 overexpression on B cells is sufficient to promote progression towards full-blown autoimmune disease in MOG-specific TCR transgenic animals.
CD70 overexpression did not alter the B cell compartment in EAE
As CD70 ligation can influence B cell proliferation and activation by reverse signaling (Arens et al., 2004a) , but also induces B cell depletion due to the formation of IFNγ producing T cells (Arens et al., 2001) , we investigated whether the increased EAE susceptibility of the 2D2xCD70 animals was associated with alterations in the B cell compartment. Non-immunized 2D2 and 2D2xCD70 mice showed comparable numbers of splenic B cells at week 7, but analysis at later time points indicated a progressive and significant drop in B cell numbers in 2D2xCD70 mice (p = 0.004 at week 9 and p = 0.009 at week 12) ( Fig. 2A and B) , suggesting that also in this model chronic costimulation through CD70 leads to B cell depletion over time (Arens et al., 2001) . Immunization with MOG protein at week 7 did not influence B cell numbers as flow cytometric analysis 10 days after immunization showed similar percentages of CD19 + cells in the spleen of 2D2 controls and 2D2xCD70 double transgenic mice (28% (23-29) versus 28% (23-34)) (Fig. 2C) . Further phenotypic and functional analysis of the splenic B cell population in immunized mice revealed similar numbers of CD19 + B cells with the CD5 + regulatory phenotype (12% (10-14) in 2D2 versus 10% (8-12) in 2D2xCD70) (Fig. 2D) . Upon ex vivo stimulation with PMA/Ionomycin/ LPS, a similar number of IL-10 producing CD5+ CD19+ B cells (data not shown) and a tendency towards decreased TNF expression by B cells in 2D2xCD70 mice (6% (5-7)) versus 2D2 littermates (8% (6-9); p = 0.054) were observed (Fig. 2E) . As to the potential impact of constitutive CD70 costimulation on autoantibodies, ELISA measurement of serum anti-MOG antibody levels at week 20 in non immunized mice actually revealed decreased titers in 2D2xCD70 mice (median OD: 0.08 (0.03-0.13)) versus 2D2 mice (median OD: 0.20, (0.16-0.23)) (Fig. 2F) . This observation was consistent with the phenotype of the CD70 single transgenic mice which show ablation of IgG antibodies (Arens et al., 2001) . Taken together, alterations in B cell numbers and function did not explain the increased susceptibility of 2D2xCD70 mice to EAE as the decreases in B cells and autoantibodies are more compatible with protection against disease progression (Ruddle et al., 1990; Ait-Oufella et al., 2010) .
CD70 overexpression by B cells increased the number of autoreactive T cells
Constitutive CD70 expression by B cells in TCR wild type mice leads to a significant expansion of effector CD4 and CD8 T cells through increased survival (Arens et al., 2001; Hendriks et al., 2003; van Gisbergen et al., 2011) . A similar effect was observed in the 2D2 background as MOG-immunized animals displayed a similar overall splenic cellularity but an increase of the CD4 + T cells in 2D2xCD70 mice (28% (26-31)) versus 2D2 littermate controls (22% (18-27); p = 0.03) (Fig. 3A) . Additional characterization showed that vβ11 + CD4+ T lymphocytes, which bear the MOG-specific TCR, represented 25% (23-29) of the total lymphocyte pool in 2D2xCD70 mice versus 20% (16-25) in 2D2 single transgenic animals immunized with MOG protein (p = 0.028) (Fig. 3B) . Analysis of non immunized animals at week 12 did not reveal a similar expansion of CD4+ T cells (28 versus 32%) (Fig. 3C) or vβ11 + CD4 + T cells (27 versus 31% at week 12) (Fig. 3D ) in 2D2xCD70 versus 2D2 mice, thus confirming that this expansion was driven by the immunization with the autoantigen.
To assess whether the expansion of the autoreactive CD4+ T cell pool in 2D2xCD70 mice was related to enhanced T cell survival upon antigenic stimulation, we collected splenocytes from mice immunized in vivo with MOG, restimulated them in vitro with the same antigen and measured T cell survival by 7-AAD staining. CD4+ T cells of 2D2xCD70 mice showed a significant albeit small survival advantage in comparison with 2D2 mice (p = 0.04 after restimulation with 1.6 μg MOG/ml, p = 0.04 with 5 μg MOG/ ml; p = 0.03 with 15 μg MOG/ml). This difference was not observed upon non-specific stimulation with anti-CD3/CD28 and upon MOG stimulation of splenocytes obtained from non immunized animals (data not shown). The frequency of CD8 + T cells, which is very small in the 2D2 genetic background, was not different between 2D2 and 2D2xCD70 mice (data not shown). Taken together, these results indicate that constitutive expression of CD70 by B cells increases the size of the autoreactive T cell pool in the 2D2xCD70 mice, probably as a result of increased survival after in vivo priming.
Constitutive CD70 expression by B cells did not alter the effector profile of autoreactive T cells
We next assessed whether the increase of autoreactive T cells upon MOG immunization in 2D2xCD70 mice was associated with an altered effector profile. Analysis of splenic vβ11 + autoreactive T cells, however, did not show a shift towards CD44 + CD62L− effector cells in immunized 2D2xCD70 (10% (6-11)) versus 2D2 mice (8% (6-10)) (Fig. 4A) . Similarly, no differences were observed in the CD44 + CD62L+ central memory and the CD44-CD62L + naïve subsets ( Fig. 4B and C) .
As both Th1 and Th17 cells play a pathogenic role in EAE (Jager et al., 2009; El-behi et al., 2010) , we next assessed whether B cell specific CD70 overexpression had a qualitative rather than quantitative effect on effector T cells. In vitro PMA/ionomycine restimulation of splenocytes recovered after in vivo immunization with MOG revealed equivalent expression of IFNγ (12% (8-16) versus 12% (10-15)) (Fig. 5A ), IL-17 (6% (3-7) versus 5% (4-7)) (Fig. 5B) , and IL-2 (16% (11-18) versus 13% (11-16)) (Fig. 5C ) by CD4+ T lymphocytes in 2D2 versus 2D2xCD70 mice. However, 2D2xCD70 splenocytes contained fewer TNFα producing CD4 T cells than the 2D2 controls (42% (34-44) versus 50% (45-53); p = 0.02) (Fig. 5D) . Consistent with these data on PMA/Ionomycin stimulation, in vitro restimulation with 0.6 μg/ml and 1.6 μg/ml of MOG led to a significant lower number of TNFα expressing autoreactive T cells in 2D2xCD70 versus 2D2 mice (p = 0.01 and p = 0.03, respectively), but this difference disappeared at higher doses (Fig. 5D) . In summary, these data indicate that constitutive CD70 overexpression by B cells did not alter the effector profile of autoreactive T cells in this model with the exception of slightly decreased TNFα production.
The constitutive expression of CD70 on B cells decreased the frequency of FoxP3+ T cells
As we did not observe a clear qualitative shift in the autoimmune effector T cells, we finally assessed whether constitutive CD70 expression by B cells might have affected the size of the regulatory T cell pool in vivo. We collected splenocytes of the 2D2 and 2D2xCD70 animals immunized with MOG protein and analyzed the expression of the transcription factor FoxP3 by CD4+ specific T lymphocytes. The percentage of vβ11 + CD4+ T cells positive for FoxP3 was significantly reduced in the 2D2xCD70 mice (3% (3-5)) versus the 2D2 littermate controls (6% (5-7); p = 0.04) (Fig. 6A) . A similar reduction in FoxP3 positive T cells was also observed in the vβ11 − CD4+ T cell subset (7% (5-8) in 2D2xCD70 versus 10% (8-15) in 2D2; p b 0.001) (Fig. 6B) . To establish whether overexpression of CD70 by B cells also affected the generation of FoxP3+ regulatory T cells in vitro, we cultured naïve 2D2 T cells with CD70 expressing B cells in vitro for 72 h in the presence of MOG and TGFβ and measured the differentiation of T lymphocytes into CD4+ FoxP3+ T cells. For all the doses of MOG peptide tested, the frequency of FoxP3 expressing T cells was significantly decreased when CD70 + B cells were used as antigen presenting cells in comparison with wild type B cells (Fig. 6C ). In conjunction with the ex vivo data, our results illustrate that CD70-mediated costimulation provided by B cells is sufficient to impair the formation of antigen-specific FoxP3+ CD4 + regulatory T cells, possibly enhancing the susceptibility to autoimmunity.
Discussion
The development of an adequate T cell response is a multi-step process requiring not only recognition of the antigen by the T cell receptor (signal 1) but also appropriate costimulation (signal 2) and instructive signals by cytokines (signal 3) to allow for proliferation, survival, and differentiation into specific effector cells. Over the last years, extensive work on CD70-CD27 has established that this costimulation pair plays an important role in determining the outcome of T cell responses . CD70, which is transiently expressed on activated lymphocytes and dendritic cells, can engage CD27 on naïve and recently activated CD4 + and CD8 + T cells and thereby contribute to the formation of the effector pool by inducing proliferation and survival. Using a model of constitutive CD70 expression by B cells, we previously demonstrated that chronic costimulation through CD70 can cause immunopathology by exhausting the T cell and B cell pools (Arens et al., 2001; Tesselaar et al., 2003) . The impact of CD70 stimulation in autoimmune disease though, has not been thoroughly explored. In contrast to overexpression of other costimulatory molecules such as OX40L (Murata et al., 2002) and LIGHT (Wang et al., 2001) , mice with constitutive expression of CD70 by B cells did not develop spontaneously autoimmune phenomena. However, these data remain difficult to interpret as B cells, which play a crucial role in many autoimmune diseases, are rapidly and profoundly depleted in an IFNγ dependent way by activated T cells in these mice (Arens et al., 2001 ). This depletion also precludes the study of classical autoimmune models such as collagen-induced arthritis and MOGinduced experimental autoimmune encephalomyelitis as B cells are crucial to the pathogenesis of these diseases (Lyons et al., 1999; Brand et al., 2003; Cho et al., 2007; Carter et al., 2012) .
Here, we circumvented this issue by using 2D2 TCR transgenic animals with specificity to MOG. These mice display clear subclinical autoimmunity but only rarely progress spontaneously to overt autoimmune disease (Bettelli et al., 2003) . B cell depletion in CD70TG mice is dependent on TCR-triggering (Tesselaar et al., 2003) . As in the 2D2 animals the majority of the peripheral T cells are specific for MOG, an autoantigen sequestered in the central nervous system, we hypothesized that unless autoimmune disease was triggered, only few (non-MOG specific) T cells would be activated by the CD70 overexpression and thus IFNγ dependent B cell depletion would be delayed and mild in the 2D2xCD70 mice versus the CD70 mice. In agreement with this hypothesis, we observed normal numbers of B cells at week 7 and progressive but incomplete B cell depletion at week 9 and 12. Hence, the 2D2 TCR transgenic mouse provides a unique opportunity to study the effect of constitutive CD70 costimulation by B cells on autoimmunity in general and on the progression of autoimmunity to overt autoimmune disease in particular. Moreover, autoreactive T cells can be easily tracked in these animals by the use of the vβ11 TCR chain; and we and others previously demonstrated that, when EAE develops in them, B cells play an important role as antigen-presenting cells (Bettelli et al., 2006; Krishnamoorthy et al., 2006) . Two types of experiments confirmed our hypothesis that CD70 costimulation can trigger and/or accelerate autoimmune disease. Firstly, 20% of the 2D2 mice overexpressing CD70 spontaneously developed EAE without MOG immunization. To extend this observation, we immunized 7 weeks old mice with MOG and observed a similar increase in incidence and severity of EAE in the presence of constitutive CD70 costimulation. We used low dosages of MOG in these experiments as 2D2 mice develop very severe EAE upon full immunization, even in the absence of CD70 costimulation (Bettelli et al., 2003) . These data are in agreement with studies showing that blocking anti-CD70 antibodies can prevent PLP-induced EAE (Nakajima et al., 2000) and suppress Theiler's murine encephalomyelitis virus-induced demyelinating disease (Yanagisawa et al., 2010) . Taken together, these data consistently indicate that CD70-mediated costimulation plays an important role in the development of T cell-dependent CNS autoimmunity.
Further analysis confirmed that the mechanisms of increased autoimmunity in the presence of constitutive CD70 expression are related to T cell rather than B cell alterations. Indeed, the number, phenotype and cytokine production of B cells was not altered upon MOG immunization in CD70 versus WT animals. Moreover, we did not observe an increase of anti-MOG antibodies in the diseases 2D2xCD70 animals versus the 2D2 littermates. In contrast with the B cell compartment, analysis of the T cells indicated two major alterations. Firstly, we observed an expansion of the autoreactive vβ11 + CD4+ T cell pool in the 2D2xCD70 mice. This expansion is triggered by antigen-exposure, as it was not observed in 12 weeks-old non-immunized animals. In vitro analysis suggested that this accumulation is most likely due to enhanced survival of the autoreactive T cells. However, in contrast with previous reports under homeostatic conditions as well as in tumour and viral infection models (Arens et al., 2004b) , this expansion was not associated with a shift towards effector-memory T cells. Functional analysis of the autoreactive T cells did not show an increase of Th1 or Th17 responses and even a moderate impairment of TNFα production. This suggests that the timing and tuning of the CD70-CD27 costimulation may be different in this autoimmune model versus the previously studied models and/or that the TCR transgenic T cells are less susceptible to these effects. Alternatively, the autoreactive T cells triggered by CD70 and MOG to develop into Th1 skewed effector cells migrate rapidly from the periphery to the CNS and can therefore not be detected in the lymphoid tissues in this model.
The second major alteration in the T cell pool was the decrease in vivo and in vitro in FoxP3 + regulatory T cells. Previous analysis did not show an impact of CD70 overexpression on the frequency and/ or activation status of T regs under homeostatic conditions (Libregts et al., 2011) , but the influence of CD70 over the course of an immune reaction may be different. Interestingly, recent studies using CD70-expressing B cells from non-Hodgkin's lymphomas and chronic lymphocytic leukemia Jak et al., 2009 ) indicated that CD70 can induce FoxP3 expression and thereby enhance formation and survival of Tregs. The CD27/CD70 pathway has also been shown to be essential for the generation of regulatory cells after intratracheal delivery of alloantigens (Aramaki et al., 2003) . Although we observe the opposite effect in our autoimmune model, which may again be related to the timing and tuning of CD70 costimulation during the immune response as well as the availability of the antigen, the concept of regulation of regulatory T cells by costimulatory molecules is not novel. Indeed, GITR-GITRL interactions were shown to promote expansion of both effector and regulatory T cells ) whereas OX40/OX40L costimulation affects the induction of T regs by expanding the memory T cell pool (Xiao et al., 2008) . Similarly, signalling of B7 molecules through CD28 and CTLA4 has been shown to affect the regulatory T cell pool (Salomon et al., 2000; Tang et al., 2003) , with important functional consequences in vivo (Poirier et al., 2010) . Our data thus indicate that CD70/CD27 interactions can reciprocally modulate the balance between autoreactive effector and regulatory T cells in autoimmunity and this shift in the balance may explain the increased incidence and severity of EAE in 2D2xCD70 transgenic mice.
The fact that enhanced expression of CD70 by B cells triggers EAE in this model provides further support for the concept that B lymphocytes may promote autoimmune disease through a variety of mechanisms. Besides terminal differentiation towards autoantibody-producing plasma cells, B cells appear to be potent antigen presenting cells able to steer autoreactive T cell responses. Their role in T cell activation appears not only to be determined by their BCR-related ability to capture and process autoantigens with high efficacy but also by their expression of costimulatory molecules. The transgenic overexpression model used in the present study may mimic to a certain extend the unchecked CD70 expression in humans during chronic viral infections and autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus (Wolthers et al., 1996; Oelke et al., 2004; Lee et al., 2007) , or the CD70-CD27 interactions evidenced in rheumatoid arthritis (Tak et al., 1996) . Strikingly, diseases such as RA and MS might be triggered by viral infections, including EBV infection of B cells (Franssila and Hedman, 2006; Sawada et al., 2007; Toussirot and Roudier, 2007; Franciotta et al., 2008; Pender, 2009 Pender, , 2011 , and show a profound clinical response to B cell depletion by anti-CD20 (Dorner et al., 2010; Townsend et al., 2010) . Whether abnormal expression of CD70 by chronically activated B cells contributes directly to the pathogenesis of these diseases remains to be further investigated. Nevertheless, this study highlights the fact that, besides CTLA-4, the blockade of other costimulatory pairs such as CD70-CD27, may hold therapeutic potential in the treatment of MS and other autoimmune diseases.
